Search Results - "Heching, N."

Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival by Nisman, B, Biran, H, Heching, N, Barak, V, Ramu, N, Nemirovsky, I, Peretz, T

“…Prognostic implication of serum cytokeratin 19 fragments (CYFRA 21-1) was explored in 60 advanced NSCLC patients, whereas in 45 patients assessable for…”
Get full text

1343P Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC by Krayim, B.J., Kian, W., Heching, N., Salhab, A.A.R., Asna, N., Kahala, D., Roisman, L.C., Peled, N.

Get full text

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women by ABELIOVICH, D, KADURI, L, LERER, I, WEINBERG, N, AMIR, G, SAGI, M, ZLOTOGORA, J, HECHING, N, PERETZ, T

“…The mutations 185delAG, 188del11, and 5382insC in the BRCA1 gene and 6174delT in the BRCA2 gene were analyzed in 199 Ashkenazi and 44 non-Ashkenazi Jewish…”
Get full text

The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer by Nisman, Benjamin, Heching, Norman, Biran, Haim, Barak, Vivian, Peretz, Tamar

“…Chromogranin A (CGA), Pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) are known as immunohistochemical tissue markers closely…”
Get more information

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information? by NISMAN, B, LAFAIR, J, HECHING, N, LYASS, O, BARAS, M, PERETZ, T, BARAK, V

“…Recently developed tissue polypeptide specific antigen (TPS) and CYFRA 21-1 assays determine the soluble cytokeratin 18 and 19 fragments, respectively, in…”
Get full text

Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer by Nisman, B, Amir, G, Lafair, J, Heching, N, Lyass, O, Peretz, T, Barak, V

“…The prognostic value of the tumor markers CYFRA 21-1, tissue polypeptide specific antigen (TPS) and carcinoembryonic antigen (CEA) was investigated in three…”
Get more information

Leptomeningeal metastases : evaluation by gadolinium enhanced spinal magnetic resonance imaging by GOMORI, J. M, HECHING, N, SIEGAL, T

“…Leptomeningeal metastases are common in patients with metastatic systemic cancer or certain primary brain tumors. They may be unsuspected clinically and may be…”
Get full text

Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers by Kaduri, Luna, Gibs, Maya, Hubert, Ayala, Sagi, Michal, Heching, Norman, Lerer, Israela, Uziely, Bietrice, Weinberg, Naomi, Abeliovich, Dvorah, Peretz, Tamar

“…Objectives: Carriers of the mutations 185delAG and 5382insC in the BRCA1 gene and 6174delT in the BRCA2 gene have a substantial life-time risk for breast and…”
Get full text

Cytokeratin markers in malignant pleural mesothelioma by Nisman, B, Barak, V, Heching, N, Kramer, M, Reinus, C, Lafair, J

“…Previously available serum tumor markers had a low clinical value in malignant pleural mesothelioma (MPM). The recently developed tissue polypeptide-specific…”
Get more information

Genetic counseling for families at high cancer risk by Sagi, M, Heching, N, Kadouri, L, Abeliovich, D, Zlotogora, J, Bach, G, Peretz, T

“…About 5-10% of the most common cancers, such as breast, colon and melanoma, result from mutations in inherited predisposition genes. Recently some of these…”
Get more information